Mechanisms of resistance to BCR-ABL and other kinase inhibitors

In this article, we are reviewing the molecular mechanisms that lead to kinase inhibitor resistance. As the oncogenic BCR-ABL kinase is the target of the first approved small-molecule kinase inhibitor imatinib, we will first focus on the structural and mechanistic basis for imatinib resistance. We will then show ways how next generations of BCR-ABL inhibitors and alternative targeting strategies have helped to offer effective treatment options for imatinib-resistant patients. Based on these insights, we discuss commonalities and further mechanisms that lead to resistance to other kinase inhibitors in solid tumors. This article is part of a Special Issue entitled: Inhibitors of Protein Kinases (2012). (C) 2012 Elsevier B.V. All rights reserved.


Published in:
Biochimica Et Biophysica Acta-Proteins And Proteomics, 1834, 7, 1449-1459
Year:
2013
Publisher:
Amsterdam, Elsevier Science Bv
ISSN:
1570-9639
Keywords:
Laboratories:




 Record created 2013-10-01, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)